APA (7th ed.) Citation

JA, S., SW, H., KW, S., NC, Y., G, D., JG, B., . . . D, L. (2022). Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors. Molecular cancer therapeutics, 21(7), 1047. https://doi.org/10.1158/1535-7163.MCT-21-0915

Chicago Style (17th ed.) Citation

JA, Scribner, et al. "Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors." Molecular Cancer Therapeutics 21, no. 7 (2022): 1047. https://doi.org/10.1158/1535-7163.MCT-21-0915.

MLA (9th ed.) Citation

JA, Scribner, et al. "Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors." Molecular Cancer Therapeutics, vol. 21, no. 7, 2022, p. 1047, https://doi.org/10.1158/1535-7163.MCT-21-0915.